Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 442

1.

Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature.

Kötter I, Henes JC, Wagner AD, Loock J, Gross WL.

Clin Exp Rheumatol. 2012 Jan-Feb;30(1 Suppl 70):S114-29. Epub 2012 May 11. Review.

PMID:
22640655
2.

A scoping review of the use of non-biologic disease modifying anti-rheumatic drugs in the management of large vessel vasculitis.

Misra DP, Sharma A, Kadhiravan T, Negi VS.

Autoimmun Rev. 2017 Feb;16(2):179-191. doi: 10.1016/j.autrev.2016.12.009. Epub 2016 Dec 15. Review.

PMID:
27988436
3.

Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review.

de Boysson H, Boutemy J, Creveuil C, Ollivier Y, Letellier P, Pagnoux C, Bienvenu B.

Semin Arthritis Rheum. 2013 Aug;43(1):105-12. doi: 10.1016/j.semarthrit.2012.12.023. Epub 2013 Feb 27. Review.

PMID:
23453684
4.

[Management of polymyalgia rheumatica and large vessel vasculitis].

Hellmich B.

Internist (Berl). 2016 Nov;57(11):1069-1078. Review. German.

PMID:
27631531
5.

Role of oral cyclophosphamide in the treatment of giant cell arteritis.

Quartuccio L, Maset M, De Maglio G, Pontarini E, Fabris M, Mansutti E, Mariuzzi L, Pizzolitto S, Beltrami CA, De Vita S.

Rheumatology (Oxford). 2012 Sep;51(9):1677-86. doi: 10.1093/rheumatology/kes127. Epub 2012 May 23.

PMID:
22627726
6.

Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.

Unizony S, Arias-Urdaneta L, Miloslavsky E, Arvikar S, Khosroshahi A, Keroack B, Stone JR, Stone JH.

Arthritis Care Res (Hoboken). 2012 Nov;64(11):1720-9. doi: 10.1002/acr.21750.

7.

Biotherapies in large vessel vasculitis.

Ferfar Y, Mirault T, Desbois AC, Comarmond C, Messas E, Savey L, Domont F, Cacoub P, Saadoun D.

Autoimmun Rev. 2016 Jun;15(6):544-51. doi: 10.1016/j.autrev.2016.02.012. Epub 2016 Feb 12. Review.

PMID:
26883459
8.

[Large vessel vasculitis: giant cell arteritis and Takayasu arteritis].

Petitpierre S, Bart PA, Leimgruber A, Spertini F, Prior J, Spertini F.

Rev Med Suisse. 2007 Apr 25;3(108):1056-60, 1062-3. Review. French.

PMID:
17552258
9.

Cyclophosphamide for large vessel vasculitis: assessment of response by PET/CT.

Henes JC, Mueller M, Pfannenberg C, Kanz L, Kötter I.

Clin Exp Rheumatol. 2011 Jan-Feb;29(1 Suppl 64):S43-8. Epub 2011 May 11.

PMID:
21385544
10.

[Treatment of large vessel vasculitis].

Alvarez-Hernández E.

Reumatol Clin. 2011 Dec;7 Suppl 3:S28-32. doi: 10.1016/j.reuma.2011.10.004. Epub 2011 Nov 13. Review. Spanish.

11.

Sustained remission after long-term biological therapy in patients with large vessel vasculitis: an analysis of ten cases.

Vinicki JP, García-Vicuña R, Arredondo M, López-Bote JP, García-Vadillo JA, Castañeda S, Álvaro-Gracia JM.

Reumatol Clin. 2017 Jul - Aug;13(4):210-213. doi: 10.1016/j.reuma.2016.06.003. Epub 2016 Aug 4. English, Spanish.

12.

Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate.

Hoffman GS, Leavitt RY, Kerr GS, Rottem M, Sneller MC, Fauci AS.

Arthritis Rheum. 1994 Apr;37(4):578-82.

PMID:
7908520
13.

Treatment of refractory giant cell arteritis with cyclophosphamide:a retrospective analysis of 35 patients from three centres.

Loock J, Henes J, Kötter I, Witte T, Lamprecht P, Schirmer M, Gross WL.

Clin Exp Rheumatol. 2012 Jan-Feb;30(1 Suppl 70):S70-6. Epub 2012 May 14.

PMID:
22640650
14.

Biologic treatment of large-vessel vasculitides.

Schäfer VS, Zwerina J.

Curr Opin Rheumatol. 2012 Jan;24(1):31-7. doi: 10.1097/BOR.0b013e32834dc392. Review.

PMID:
22089099
15.

Standard and biological treatment in large vessel vasculitis: guidelines and current approaches.

Muratore F, Pipitone N, Salvarani C.

Expert Rev Clin Immunol. 2017 Apr;13(4):345-360. doi: 10.1080/1744666X.2017.1285699. Epub 2017 Feb 6. Review.

PMID:
28116918
16.

Effects of immunosuppressive and biological agents on refractory Takayasu arteritis patients unresponsive to glucocorticoid treatment.

Ohigashi H, Tamura N, Ebana Y, Harigai M, Maejima Y, Ashikaga T, Isobe M.

J Cardiol. 2017 May;69(5):774-778. doi: 10.1016/j.jjcc.2016.07.009. Epub 2016 Aug 25.

PMID:
27567177
17.

Takayasu arteritis in children: preliminary experience with cyclophosphamide induction and corticosteroids followed by methotrexate.

Ozen S, Duzova A, Bakkaloglu A, Bilginer Y, Cil BE, Demircin M, Davin JC, Bakkaloğlu M.

J Pediatr. 2007 Jan;150(1):72-6.

PMID:
17188618
18.

Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis.

Shinjo SK, Pereira RM, Tizziani VA, Radu AS, Levy-Neto M.

Clin Rheumatol. 2007 Nov;26(11):1871-5. Epub 2007 Feb 28.

PMID:
17332971
19.

Treatment and outcomes of large vessel arteritis.

Borg FA, Dasgupta B.

Best Pract Res Clin Rheumatol. 2009 Jun;23(3):325-37. doi: 10.1016/j.berh.2009.04.001. Review.

PMID:
19508941
20.

Management of Takayasu arteritis: a systematic review.

Keser G, Direskeneli H, Aksu K.

Rheumatology (Oxford). 2014 May;53(5):793-801. doi: 10.1093/rheumatology/ket320. Epub 2013 Oct 4. Review.

PMID:
24097290

Supplemental Content

Support Center